Jun 27 |
Cerevel Therapeutics gains on report Tempur Sealy will be the subject of FTC meeting (update)
|
Jun 25 |
Cerevel Therapeutics sinks amid some worry on FTC review of AbbVie deal
|
Jun 13 |
Cerevel Therapeutics seesaws amid FTC notice on closed door meeting
|
Jun 12 |
Cerevel Therapeutics gains after AbbVie says making good progress with FTC
|
Jun 4 |
Cerevel Therapeutics: Time For A Risk Arbitrage Play?
|
Apr 18 |
Heard on the Street: AbbVie’s Bet on a Neuroscience Drug Maker Just Got Better
|
Apr 18 |
AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug
|
Apr 18 |
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
|
Mar 6 |
Cerevel Therapeutics: Parkinson's Could Be The Issue
|
Feb 16 |
Cerevel, AbbVie get FTC Second Requests for more merger info
|